NCT05704530 is a NA clinical trial of Blood sample in Esophageal Cancer, sponsored by Universitaire Ziekenhuizen KU Leuven.

Who is sponsoring NCT05704530?

NCT05704530 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What drugs are being tested in NCT05704530?

Interventions in NCT05704530: Blood sample.

What condition does NCT05704530 study?

NCT05704530 studies Esophageal Cancer.

Is NCT05704530 still recruiting?

NCT05704530 is currently recruiting now. Last updated 1 July 2024.

Last reviewed 2024-07-01 · How we verify

NCT05704530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liquid Biopsies in Esophageal Cancer

Recruiting now NA Last updated 1 July 2024

What this trial tests

NA trial testing Blood sample in Esophageal Cancer in 248 participants. Currently enrolling.

Timeline

29 March 2023

Primary endpoint
30 September 2025

31 December 2026

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	248
Start date	29 March 2023
Primary completion	30 September 2025
Estimated completion	31 December 2026
Sites	4 locations across Belgium

Drugs / interventions tested

Blood sample — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

18 and older, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.
Shen F, Zailaie SA, Chiu B, Magliocco A, et al · · 2025 · cited 2× · PMID 40772765 · DOI 10.1080/20565623.2025.2527598

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05704530 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 1 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05704530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing